NDATOPICALAEROSOL, FOAM
Approved
Oct 2013
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
ECOZA (econazole nitrate) by PharmaIN is 12. Approved for interdigital tinea pedis caused by trichophyton rubrum, trichophyton mentagrophytes, epidermophyton floccosum in patients 12 years of age and 1 more indications. First approved in 2013.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ECOZA is a topical azole antifungal foam containing econazole nitrate 1% approved for interdigital tinea pedis in patients 12 years and older. It works by inhibiting fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylase, disrupting ergosterol synthesis in the fungal cell wall. The product is administered once-daily as a topical aerosol foam to affected foot areas.
Peak5.0 years to LOE
ECOZA is in peak commercial lifecycle with formulation patent protection through August 2031, supporting stable commercial operations but modest team expansion potential.
Mechanism of Action
12.1 Mechanism of Action Ecoza topical foam is an azole antifungal [ see ] . 12.2 Pharmacodynamics The pharmacodynamics of Ecoza topical foam, 1% have not been established . 12.3 Pharmacokinetics The systemic absorption of Ecoza topical foam, 1% following topical application was studied in one…
Worked on ECOZA at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.